Bausch Health Companies (TSX:BHC) - Aandelenkoers, Nieuws & Analyse

BHC Overzicht aandelen

Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische apparatuur in de Verenigde Staten en internationaal. Meer informatie

BHC fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 83.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 218.28% per jaar groeien

De winst is de afgelopen 5 jaar met 34.6% per jaar gegroeid

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Negatief eigen vermogen

Bausch Health Companies Inc. Concurrenten

Green Thumb Industries

CNSX:GTII

CA$3.1b

Curaleaf Holdings

TSX:CURA

CA$2.1b

Trulieve Cannabis

CNSX:TRUL

CA$1.6b

Cronos Group

TSX:CRON

CA$1.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bausch Health Companies
Historische aandelenkoersen
Huidige aandelenkoers	US$11.39
52 Week Hoogtepunt	US$15.43
52 Week Laag	US$5.45
Bèta	0.74
11 maand verandering	0%
3 maanden verandering	44.36%
1 Jaar Verandering	18.77%
33 jaar verandering	-61.38%
5 jaar verandering	-69.90%
Verandering sinds IPO	1,785.23%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BHC	CA Pharmaceuticals	CA Markt
7D	-0.8%	0.03%	1.3%
1Y	18.8%	-20.8%	23.7%

Rendement versus industrie: BHC overtrof de Canadian Pharmaceuticals industrie, die het afgelopen jaar een rendement -20.8 % opleverde.

Rendement versus markt: BHC presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 23.7 % opleverde.

Prijsvolatiliteit

Is BHC's price volatile compared to industry and market?
BHC volatility
BHC Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	11.6%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	3.0%

Stabiele aandelenkoers: BHC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BHC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische hulpmiddelen in de Verenigde Staten en internationaal. Het bedrijf ontwikkelt, produceert en verkoopt een scala aan producten, voornamelijk op het gebied van gastro-enterologie, hepatologie, neurologie, dermatologie, internationale farmaceutica, receptvrije producten (OTC), esthetische medische hulpmiddelen en ooggezondheid. Het bedrijf is actief in vijf segmenten: Salix, International, Solta Medical, Diversified en Bausch + Lomb.

Bausch Health Companies Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Bausch Health Companies zich tot de beurswaarde?
BHC fundamentele statistieken
Marktkapitalisatie	CA$4.07b
Inkomsten(TTM)	-CA$249.64m
Inkomsten(TTM)	CA$13.29b

0.3x

P/S-verhouding

-16.8x

Koers/Winstverhouding

Is BHC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BHC resultatenrekening (TTM)
Inkomsten	US$9.47b
Kosten van inkomsten	US$2.76b
Brutowinst	US$6.71b
Overige uitgaven	US$6.89b
Inkomsten	-US$178.00m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.48
Brutomarge	70.87%
Nettowinstmarge	-1.88%
Schuld/Eigen Vermogen Verhouding	-8,887.2%

Hoe presteerde BHC op de lange termijn?

Bekijk historische prestaties en vergelijking

BHC Overzicht aandelen

Beloningen

Risicoanalyse

Bausch Health Companies Inc. Concurrenten

CNSX:GTII

CA$3.1b

TSX:CURA

CA$2.1b

CNSX:TRUL

CA$1.6b

TSX:CRON

CA$1.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold CA$932k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings: EPS and revenues miss analyst expectations